Dickkopf-1 is a master regulator of joint remodeling

By Danielle Diarra, M. Stolina, K. Polzer, J. Zwerina, M. Ominsky, D. Dwyer, A. Korb, J. Smolen, M. Hoffmann, C. Scheinecker and 5 more. Nature Medicine, 2007

1,345 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/ff34e51990abd9c2144c13bd91acdd71fcc161fd

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. J. Smolen
2. M. Goldring
3. Georg Schett
4. K. Redlich
5. Gary S. Firestein
6. I. McInnes
7. Daniel Aletaha

In Oncology

1. Gary S. Firestein
2. I. McInnes
3. J. Smolen
4. Georg Schett
5. K. Redlich
6. S. Gaffen
7. Daniel Aletaha

Citations in the corpus

• Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. (2008, background): “In patients with ankylosing spondylitis, the serum concentrations of DKK-1 were lower than those seen in healthy individuals, whereas concentrations were above normal in patients with RA (Diarra et al., 2007).”
• Cartilage homeostasis in health and rheumatic diseases (2009, background): “A link between RANKL and WNT has been suggested by findings in hTNFtg mice and RA tissues, in which decreased β-catenin and high DKK-1, a WNT inhibitor, were demonstrated in synovium and in cartilage adjacent to inflammatory tissue [199] (reviewed in [200]).”
• Inflammatory bone loss: pathogenesis and therapeutic intervention (2012, background): “but readily secreted by cytokine-activated or malignant cell”
• Cytokines in the pathogenesis of rheumatoid arthritis (2007, background): “TNF upregulates secretory molecules, such as dickkopf homologue 1 (DKK1), which acts as a WNT-protein inhibitor and blocks bone and cartilage formatio”
• Immunopathogenesis of rheumatoid arthritis (2017, positive): “osteoclast and osteoblast co-regulators suggest the intriguing possibility of promoting bone healing—this has not yet been possible on the basis of existing therapeutics (Diarra et al., 2007; McInnes and Schett, 2011).”